BioProcess International US East 2026

Future-Proofing Your Cell Line Development (CLD) Workflow: Leveraging Automation for Scalable Growth and Product Consistency

Date and Time: 23 September, 1:00 pm
Location: TBD

As biologics development accelerates, scientists face mounting pressures to increase productivity without compromising product quality or consistency. Progressive scalability through strategic automation holds the key to overcoming these challenges. In this session, we’ll discuss how to thoughtfully introduce automation across critical CLD steps - from clone isolation through analytical screening - to build robust workflows capable of scaling as therapeutic pipelines expand. Participants will gain actionable insights into establishing adaptive, scalable processes, enhancing throughput, and reliably maintaining critical quality attributes. This presentation offers practical scientific guidance for professionals seeking to future-proof their CLD workflows through effective automation strategies.

Presented by Alicia Barker, Scientist, Cell Line Development, Just - Evotec Biologics

Alicia Barker is a Scientist on the Cell Line Development team at Just - Evotec Biologics in Seattle, Washington. She has played a pivotal role in the development of multiple cell lines expressing therapeutic drug candidates for commercial manufacturing. In her current position, Alicia focuses on the design and implementation of high-throughput methods and automation strategies, aimed at expanding the capabilities and efficiency of the cell line development process. Her work contributes to advancing the company’s mission to accelerate and expand access to biotherapeutics.

J.Media^TM: A Concentratable, Room Temperature Stable Perfusion Media For High Biotherapeutic Productivity and Robust Scalability in CHO Cell Culture Platforms

CHO-based Continuous perfusion bioprocessing can offer highly intensified biologics production processes at a fraction of the scale and raw material cost of a traditional fed-batch process but require cell culture media optimization to meet the challenges of high-intensity, long-duration perfusion campaigns. Just - Evotec Biologics has developed a proprietary chemically-defined (CD), animal origin free (AOF), Chinese Hamster Ovary (CHO) perfusion cell culture medium, “J.Media”. Developed to maximize cell viability and titer across scales, it can be concentrated up to 5x and stored at room temperature, which can reduce storage footprint and cold storage requirements for large scale manufacturing campaigns.  In addition, the medium can be consumed as either powder or liquid.

J.Media performance was evaluated against leading market perfusion media. J.Media performance was compared against 3 commercially available perfusion media in two J.CHO stable cell lines, each producing separate IgG1 sequences (mAb1 and mAb2).  In an 8-day, unbled 24-deep well plate mock perfusion experimental set-up, cells cultured in J.Media exhibited higher volumetric productivity and cumulative titer than the commercially available media tested. We hypothesize that J.Media medium formulations supported better protein production through efficient shuttling of nutrients to protein production cellular machinery as demonstrated by lower specific ammonia and lactate production compared to other evaluated media.

J.Media scalability was further assessed by comparing mAb1 and mAb2 production at 3 L and 500 L scales. Both 3 L and 500 L scale production runs demonstrated similar cumulative titers normalized to bioreactor volume and similar product quality, specifically size variants and glycosylation profiles despite some differences in cell density, volumetric productivity, and viability across scales. These differences are likely due to differences in cell bleed control methods across scales.

Taken together, these data demonstrate Just - Evotec Biologics J.Media provides a scalable, room temperature-stable perfusion medium that should be considered when selecting for high intensity CHO-based perfusion biologics production. 

Presented by Matthew Stebbins, Associate Director, Media Development at Just - Evotec Biologics